Show simple item record

dc.contributor.authorDe Grey, Aubrey D N J
dc.contributor.authorCampbell, F Charles
dc.contributor.authorDokal, Inderjeet
dc.contributor.authorFairbairn, Leslie J
dc.contributor.authorGraham, Gerry J
dc.contributor.authorJahoda, Colin A B
dc.contributor.authorPorterg, Andrew C G
dc.date.accessioned2009-08-21T10:21:20Z
dc.date.available2009-08-21T10:21:20Z
dc.date.issued2004-06
dc.identifier.citationTotal deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers. 2004, 1019:147-70 Ann. N. Y. Acad. Sci.en
dc.identifier.issn0077-8923
dc.identifier.pmid15247008
dc.identifier.doi10.1196/annals.1297.026
dc.identifier.urihttp://hdl.handle.net/10541/78131
dc.description.abstractDespite enormous effort, progress in reducing mortality from cancer remains modest. Can a true cancer "cure" ever be developed, given the vast versatility that tumors derive from their genomic instability? Here we consider the efficacy, feasibility, and safety of a therapy that, unlike any available or in development, could never be escaped by spontaneous changes of gene expression: the total elimination from the body of all genetic potential for telomere elongation, combined with stem cell therapies administered about once a decade to maintain proliferative tissues despite this handicap. We term this therapy WILT, for whole-body interdiction of lengthening of telomeres. We first argue that a whole-body gene-deletion approach, however bizarre it initially seems, is truly the only way to overcome the hypermutation that makes tumors so insidious. We then identify the key obstacles to developing such a therapy and conclude that, while some will probably be insurmountable for at least a decade, none is a clear-cut showstopper. Hence, given the absence of alternatives with comparable anticancer promise, we advocate working toward such a therapy.
dc.language.isoenen
dc.subjectCanceren
dc.subjectCancer Metastasisen
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents
dc.subject.meshBone Marrow Cells
dc.subject.meshCell Aging
dc.subject.meshDNA
dc.subject.meshDisease Progression
dc.subject.meshGene Deletion
dc.subject.meshHumans
dc.subject.meshImmune System
dc.subject.meshMice
dc.subject.meshMice, Knockout
dc.subject.meshModels, Biological
dc.subject.meshMutation
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasms
dc.subject.meshStem Cells
dc.subject.meshTelomerase
dc.subject.meshTelomere
dc.titleTotal deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers.en
dc.typeArticleen
dc.contributor.departmentDepartment of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, UK. ag24@gen.cam.ac.uken
dc.identifier.journalAnnals of the New York Academy of Sciencesen
html.description.abstractDespite enormous effort, progress in reducing mortality from cancer remains modest. Can a true cancer "cure" ever be developed, given the vast versatility that tumors derive from their genomic instability? Here we consider the efficacy, feasibility, and safety of a therapy that, unlike any available or in development, could never be escaped by spontaneous changes of gene expression: the total elimination from the body of all genetic potential for telomere elongation, combined with stem cell therapies administered about once a decade to maintain proliferative tissues despite this handicap. We term this therapy WILT, for whole-body interdiction of lengthening of telomeres. We first argue that a whole-body gene-deletion approach, however bizarre it initially seems, is truly the only way to overcome the hypermutation that makes tumors so insidious. We then identify the key obstacles to developing such a therapy and conclude that, while some will probably be insurmountable for at least a decade, none is a clear-cut showstopper. Hence, given the absence of alternatives with comparable anticancer promise, we advocate working toward such a therapy.


This item appears in the following Collection(s)

Show simple item record